Applied Therapeutics Logo
US03828A1016
A2PHHB
APLT

Applied Therapeutics

Cargando cotizaciones...

Previsión

El precio objetivo medio de los analistas es de 0,23 € (+163,46 %). La mediana es de 0,23 € (+163,46 %).

Comprar
  5
Mantener
  5
Vender
  1

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Applied Therapeutics delisted from Nasdaq after takeover by Cycle Group

    Applied Therapeutics has completed its merger with Cycle Group Holdings and is now an indirect wholly owned subsidiary of Cycle Group. Cycle Group subsidiary AT2B acquired all outstanding shares for $0.088 per share; shareholders also received a non-tradable CVR with potential payments of up to $0.40. Applied filed to suspend trading, delist and deregister with the SEC; the board and several executives resigned, and James Harrison took over leadership. Cycle is integrating the lead drug candidate Govorestat into its portfolio; analysts sharply cut ratings and price targets for Applied stock following the transaction. » Más en de.investing.com


  • Cycle extends takeover offer for Applied Therapeutics

    Cycle Group Holdings has extended the deadline for its takeover offer for Applied Therapeutics to 11:59 p.m. ET on January 29, 2026. Cycle is offering $0.088 per share in cash plus a non-tradable contingent value right; the price is close to the stock’s 52-week low. The board of directors of Applied Therapeutics unanimously recommends tendering the shares and warns that, if tendering is insufficient, liquidation and the immediate repayment of an $8.5 million promissory note to Cycle would likely follow. Financial data show a weak financial picture with negative EBITDA and significant financial challenges for Applied Therapeutics. » Más en de.investing.com


  • Applied Therapeutics explores strategic alternatives and cuts 46% of workforce

    Applied Therapeutics has launched a process to evaluate strategic options such as M&A, partnerships and licensing agreements to maximize shareholder value. At the same time, the company is reducing costs by cutting 46% of its workforce; it did not disclose exact employee numbers. The stock fell sharply last year and the company reported a negative EBITDA of USD 99.61 million, but says it has more cash than debt. Applied Therapeutics is reviewing FDA Type C meeting minutes for its lead candidate govorestat and considering next steps, after also agreeing a $75 million share sale facility with Cantor Fitzgerald. » Más en de.investing.com


  • Applied Therapeutics stock plunges after uncertainty in FDA approval process for Govorestat

    Applied Therapeutics shares fell about 55% in pre-market trading after the company said the next steps for a Govorestat approval filing, including a potential accelerated submission, have not been determined. Applied is waiting for the official FDA meeting minutes to decide how to proceed; it had previously aimed for a submission in Q3 2025. Govorestat is being developed to treat the rare neuropathy CMT‑SORD and already has multiple regulatory special designations in the US and Europe. » Más en de.investing.com


  • FDA discussion on Govorestat sends Applied Therapeutics stock sharply higher

    Applied Therapeutics completed a meeting with the FDA about a potential regulatory filing for Govorestat to treat CMT‑SORD. The stock jumped sharply after investors learned of the discussion; the company is now waiting for the official meeting minutes before determining next steps. Govorestat has orphan drug status from the FDA and EMA and is also being developed for other rare diseases. Applied Therapeutics has also entered an agreement for an at‑the‑market equity offering of up to USD 75 million to raise capital. » Más en de.investing.com

Datos financieros de la empresa

En el último trimestre, Applied Therapeutics tuvo unos ingresos de 852,13 mil € y un beneficio neto de -16,18 M €
(EUR) septiembre de 2025
YoY
Ingresos 852,13 mil -
Beneficio bruto 852,13 mil -
Beneficio neto -16,18 M -
EBITDA -16,09 M -

Datos fundamentales

Métrica Valor
Capitalización bursátil
13,5 M €
Número de acciones
144,3 M
Máximo/mínimo de 52 semanas
1,36 € - 0,0818 €
Dividendos No
Beta
2,08
Ratio P/E
-0,37
Ratio PEG
0,00
Ratio P/B
-26,72
Ratio P/S
14,86

Perfil de la empresa

Applied Therapeutics, Inc., una empresa biofarmacéutica en fase clínica, desarrolla productos novedosos dirigidos a la enfermedad cardiovascular, la galactosemia y las complicaciones diabéticas. Su principal candidato a producto es AT-007, que ha completado la fase 1/2 para el tratamiento de la galactosemia en voluntarios sanos y adultos, y que se encuentra en un estudio clínico pediátrico para el tratamiento de la galactosemia en niños; para el tratamiento de la deficiencia de sorbitol deshidrogenasa; y para el tratamiento de la enzima fosfomannomutasa CDG. La empresa también desarrolla AT-001, que se encuentra en ensayos clínicos de fase III para el tratamiento de la miocardiopatía diabética, así como para el tratamiento de la neuropatía periférica diabética. Sus productos en fase preclínica incluyen AT-003 para el tratamiento de la retinopatía diabética; AT-104, un inhibidor de PI3K para el tratamiento de la leucemia linfoblástica aguda de células T, una neoplasia hematológica huérfana. Applied Therapeutics, Inc. se constituyó en 2016 y tiene su sede en Nueva York, Nueva York.

Nombre
Applied Therapeutics
CEO
Les D. Funtleyder
Sede New York City, ny
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
14/05/2019
Empleados 35

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
APLT
Frankfurt
2UV.F
Düsseldorf
2UV.DU
München
2UV.MU
🍪

Parqet  usa cookies. Más información